-
EP1409007
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP1409007
| EP1409007 - PHARMACEUTICAL COMPOSITIONS WHICH INHIBIT VASCULAR PROLIFERATION AND METHOD OF USE THEREOF [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 21.12.2012 Database last updated on 15.06.2024 | Most recent event Tooltip | 21.12.2012 | Application deemed to be withdrawn | published on 23.01.2013 [2013/04] | Applicant(s) | For all designated states IPSEN PHARMA 65 Quai Georges Gorse 92100 Boulogne-Billancourt / FR | [2009/11] |
| Former [2004/17] | For all designated states SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES S.A.S. 51-53 rue du Docteur Blanche 75016 Paris / FR | Inventor(s) | 01 /
DEWITT CULLER, Michael 17 Ledgestone Drive Hopkinton, MA01748 / US | 02 /
DANESI, Romano 99 Viale Ugo Foscolo I-57121 Livorno / IT | 03 /
BOCCI, Guido 80, Via Pieve di Santo Stefano Saint' Alessio I-55100 Lucca / IT | 04 /
DELTACCA, Mario 3, Lungarno Buozzi I-56100 Pisa / IT | [2004/17] | Representative(s) | Taylor, Kate Laura, et al HGF Limited Saviour House 9 St Saviourgate York YO1 8NQ / GB | [N/P] |
| Former [2007/33] | Taylor, Kate Laura, et al Harrison Goddard Foote 106 Micklegate York YO1 6JX / GB | ||
| Former [2007/04] | Taylor, Kate Laura Harrison Goddard Foote Fountain Precinct Balm Green Sheffield S1 2JA / GB | ||
| Former [2006/16] | Dufresne, Guillaume Alain François IPSEN (SCRAS) Direction Propriété Intellectuelle 24, rue Erlanger 75016 Paris / FR | ||
| Former [2004/25] | Hall, Robert Leonard Harrison Goddard Foote, Fountain Precinct, Balm Green Sheffield S1 2JA / GB | ||
| Former [2004/17] | Harrison Goddard Foote Fountain Precinct, Leopold Street Sheffield S1 2QD / GB | Application number, filing date | 02709045.5 | 14.01.2002 | [2004/17] | WO2002US01125 | Priority number, date | US20010261439P | 12.01.2001 Original published format: US 261439 P | US20010275294P | 13.03.2001 Original published format: US 275294 P | [2004/17] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | WO02064160 | Date: | 22.08.2002 | Language: | EN | [2002/34] | Type: | A2 Application without search report | No.: | EP1409007 | Date: | 21.04.2004 | Language: | EN | The application published by WIPO in one of the EPO official languages on 22.08.2002 takes the place of the publication of the European patent application. | [2004/17] | Search report(s) | International search report - published on: | EP | 19.02.2004 | Classification | IPC: | A61K38/31, A61K31/404, A61P43/00 | [2004/17] | CPC: |
A61K31/403 (EP,US);
A61K38/31 (EP,KR,US);
A61K31/404 (EP,US);
A61P1/04 (EP);
A61P15/08 (EP);
A61P17/00 (EP);
A61P17/02 (EP);
A61P17/06 (EP);
A61P17/12 (EP);
A61P19/02 (EP);
A61P19/08 (EP);
A61P27/06 (EP);
A61P29/00 (EP);
A61P3/10 (EP);
A61P35/00 (EP);
A61P35/02 (EP);
A61P37/02 (EP);
A61P37/08 (EP);
A61P39/00 (EP);
A61P43/00 (EP);
A61P7/00 (EP);
A61P7/04 (EP);
A61P9/00 (EP);
A61P9/08 (EP);
A61P9/10 (EP)
(-)
| Designated contracting states | AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR [2004/17] | Extension states | AL | Not yet paid | LT | Not yet paid | LV | Not yet paid | MK | Not yet paid | RO | Not yet paid | SI | Not yet paid | Title | German: | PHARMAZEUTISCHE ZUSAMMENSETZUNGEN, DIE DIE VASKULÄRE PROLIFERATION HEMMEN UND METHODEN ZU DEREN VERWENDUNG | [2004/17] | English: | PHARMACEUTICAL COMPOSITIONS WHICH INHIBIT VASCULAR PROLIFERATION AND METHOD OF USE THEREOF | [2004/17] | French: | COMPOSITIONS PHARMACEUTIQUES INHIBANT LA PROLIFERATION VASCULAIRE ET LEUR METHODE D'UTILISATION | [2004/17] | Entry into regional phase | 25.06.2003 | National basic fee paid | 25.06.2003 | Designation fee(s) paid | 25.06.2003 | Examination fee paid | Examination procedure | 27.06.2002 | Request for preliminary examination filed International Preliminary Examining Authority: EP | 25.06.2003 | Amendment by applicant (claims and/or description) | 25.06.2003 | Examination requested [2004/17] | 03.05.2004 | Despatch of a communication from the examining division (Time limit: M06) | 09.11.2004 | Reply to a communication from the examining division | 19.09.2005 | Despatch of a communication from the examining division (Time limit: M06) | 28.03.2006 | Reply to a communication from the examining division | 08.11.2006 | Despatch of a communication from the examining division (Time limit: M04) | 13.03.2007 | Reply to a communication from the examining division | 01.08.2012 | Application deemed to be withdrawn, date of legal effect [2013/04] | 20.09.2012 | Despatch of communication that the application is deemed to be withdrawn, reason: renewal fee not paid in time [2013/04] | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 03.05.2004 | Fees paid | Renewal fee | 26.01.2004 | Renewal fee patent year 03 | 20.01.2005 | Renewal fee patent year 04 | 27.01.2006 | Renewal fee patent year 05 | 29.01.2007 | Renewal fee patent year 06 | 14.01.2008 | Renewal fee patent year 07 | 14.01.2009 | Renewal fee patent year 08 | 13.01.2010 | Renewal fee patent year 09 | 14.01.2011 | Renewal fee patent year 10 | Penalty fee | Additional fee for renewal fee | 31.01.2012 | 11 M06 Not yet paid |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [A]WO9607398 (SOD CONSEILS RECH APPLIC [FR], et al) [A] 1-16* claims 1,2 *; | [X]WO9949884 (JUVANTIA PHARMA LTD OY [FI], et al) [X] 1-4,7-9,12-14 * page 5; claims 1-4,7; table 1 * * page 6, lines 20-30 *; | [X]WO9956769 (SOD CONSEILS RECH APPLIC [FR], et al) [X] 1-5,7,8,13,15,16 * page 29, line 15.25; examples 108-110,118; claims 13,14,17,18,31 *; | [X]WO9965508 (PEPTOR LTD [IL], et al) [X] 1-5,7,8,12,13 * page 59; claims 35,35 *; | [X]WO0012111 (UNIV BRITISH COLUMBIA [CA], et al) [X] 1-4,7,8,13,15,16 * abstract * * page 21, lines 11-20 *; | [X] - BARRIE R ET AL, "INHIBITION OF ANGIOGENESIS BY SOMATOSTATIN AND SOMATOSTATIN-LIKE COMPOUNDS IS STRUCTURALLY DEPENDENT", JOURNAL OF SURGICAL RESEARCH, ACADEMIC PRESS INC., SAN DIEGO, CA, US, (1993), vol. 4, no. 55, ISSN 0022-4804, pages 446 - 450, XP001063285 [X] 1-4,7,8,12,13 * see discussion;; figures 1,2 * DOI: http://dx.doi.org/10.1006/jsre.1993.1167 | [X] - MCCOMBE M ET AL, "EFFECT OF A LONG-ACTING SOMATOSTATIN ANALOGUE (BIM23014) ON PROLIFERATIVE DIABETIC RETINOPATHY: A PILOT STUDY", EYE, ROYAL COLLEGE OF OPHTALMOLOGISTS, LONDON, GB, (1991), vol. 5, no. 5, pages 569 - 575, XP001031225 [X] 1-4,7,8,12,13,15 * abstract * | [T] - AAVIK EINARI ET AL, "Elimination of vascular fibrointimal hyperplasia by somatostatin receptor 1,4-selective agonist.", THE FASEB JOURNAL: OFFICIAL PUBLICATION OF THE FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY. UNITED STATES MAY 2002, (200205), vol. 16, no. 7, ISSN 1530-6860, pages 724 - 726, XP008014600 [T] 1-4,7,9 * abstract * |